Provider-guided programs
How is peptide therapy monitored?
Responsible therapy includes a monitoring plan set by the prescribing provider: baseline labs where indicated, scheduled follow-ups, symptom and side-effect tracking, and clear adverse-event reporting. If a program prescribes without any follow-up plan, that is a warning sign, not a convenience.
What monitoring typically includes
- Baseline labs relevant to the therapy (e.g., metabolic panels, hormone axes)
- Scheduled provider follow-ups
- Symptom and side-effect logs — our journal tools help members organize these
- Defined stop or reassess criteria
Reporting adverse events
Contact your prescribing provider first for any concerning reaction. Suspected adverse events involving any drug product can also be reported to FDA MedWatch. Member support can help you locate reporting channels but never replaces clinical care.
What members track on-platform
Saved calculator results and journal entries help you arrive at follow-ups with organized data. This is record-keeping, not diagnosis — the platform never interprets clinical results.
References
- US Food and Drug Administration (2024). FDA's concerns with unapproved GLP-1 drugs used for weight loss. FDA Drug Alerts and Statements. SourceAgency notice
- US Food and Drug Administration (2023). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA Human Drug Compounding. SourceAgency notice
- US Food and Drug Administration (2023). Human drug compounding: compounded drugs are not FDA-approved. FDA. SourceAgency guidance
Found an error? Report a correction.